The GLP-1 family of medications (and the new Dr
Its also important to note that stopping the medication, especially without professional support and guidance, often leads to some degree of weight regain
Where GLP-1 agonists often produce a sensation of fullness and food aversion (sometimes to the point of gastrointestinal discomfort ), amylin-based satiety typically manifests as a more gentle reduction in hunger drive
Body Composition Changes Modern obesity medicine focuses on body composition rather than simple weight loss
More serious risks are also possible, though rare
Additionally, SRY-box transcription factor 9 (Sox9) and Krppel-like factor 4 (Klf4) transcription factors, are Paneth and goblet cell-specific differentiation factors [22, 23]